<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531957</url>
  </required_header>
  <id_info>
    <org_study_id>ASN002AD-201</org_study_id>
    <nct_id>NCT03531957</nct_id>
  </id_info>
  <brief_title>Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asana BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asana BioSciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects&#xD;
      with moderate to severe atopic dermatitis (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo controlled study where subjects with moderate to severe atopic dermatitis&#xD;
      will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once&#xD;
      daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month&#xD;
      open-label extension study (OLE). There will be a 4-week follow up period for subjects not&#xD;
      participating in the OLE study. This study will also characterize the pharmacokinetics and&#xD;
      pharmacodynamics of ASN002 through blood sampling and three or four biopsies from subjects&#xD;
      who consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Actual">August 14, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in EASI at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 50% reduction from baseline in EASI (EASI50)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Reduction of EASI compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 75% reduction from baseline in EASI (EASI75)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Reduction of EASI compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 90% reduction from baseline in EASI (EASI90)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Reduction of EASI compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 5-D Pruritus (itching) Scale</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Change from baseline in 5-D Pruritus (itching) Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Change from baseline in SCORing Atopic Dermatitis (SCORAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with a Response of Investigator's Global Assessment (IGA) 0 or 1</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Proportion of Participants with a Response of IGA 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient-Oriented Eczema Measure (POEM)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Change from baseline in POEM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Change from baseline in DLQI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Surface Area (BSA)</measure>
    <time_frame>2, 4, 8, and 12 weeks</time_frame>
    <description>Change from baseline in BSA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>ASN002 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg ASN002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN002 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg ASN002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN002 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg ASN002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo for ASN002 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASN002</intervention_name>
    <description>Daily dose of ASN002 for 12 weeks</description>
    <arm_group_label>ASN002 40 mg</arm_group_label>
    <arm_group_label>ASN002 60 mg</arm_group_label>
    <arm_group_label>ASN002 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo of ASN002 for 12 weeks</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained prior to any study-related procedure being&#xD;
             performed;&#xD;
&#xD;
               -  Male or female, 18≤ years and ≤75 years of age with chronic AD for at least 6&#xD;
                  months.&#xD;
&#xD;
               -  At least 10% body surface area (BSA) of AD involvement at the baseline visits&#xD;
&#xD;
               -  Has a body mass index (BMI) ≤35 kg/m2&#xD;
&#xD;
               -  History of inadequate response to topical corticosteroids or calcineurin&#xD;
                  inhibitors as treatment for AD within 1 year before the screening visit.&#xD;
&#xD;
               -  Willing to apply only a basic bland emollient once or twice-daily for at least 7&#xD;
                  days before the baseline visit.&#xD;
&#xD;
               -  Willing to comply with discontinuation of certain treatments for AD, as directed&#xD;
                  by the Investigator.&#xD;
&#xD;
               -  Willing to use medically effective methods of birth control&#xD;
&#xD;
               -  Females of reproductive potential must have a negative serum pregnancy test at&#xD;
                  screening and negative urine pregnancy test at Day 1..&#xD;
&#xD;
               -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically infected atopic dermatitis.&#xD;
&#xD;
               -  Presence of any of the following laboratory abnormalities at the screening visit:&#xD;
                  Hemoglobin &lt; 11 g/dL, White blood cell (WBC) &lt; 3.0 x 103 /μL, Platelet count &lt;&#xD;
                  125 x 103 /μL, Neutrophils &lt; &lt; 2.50 x 103 /μL, Lymphocytes ≤ 1.2 x 103 /μL,&#xD;
                  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 1.5 x the upper&#xD;
                  limit of normal (ULN),Total bilirubin &gt; ULN (except for elevated indirect&#xD;
                  bilirubin secondary to Gilbert's syndrome), Creatinine &gt; ULN&#xD;
&#xD;
               -  A serious uncontrolled condition including hypertension, history of tuberculosis,&#xD;
                  hepatitis B or C infection, immune deficiency, heart disease, heart conduction&#xD;
                  disorder, diverticulitis, diabetes, reflux disease requiring protocol pump&#xD;
                  inhibitor therapy, malabsorption syndrome, or cancer.&#xD;
&#xD;
               -  Any condition requiring the use of anticoagulants.&#xD;
&#xD;
               -  History of hypertrophic scarring or keloid formation in scars or suture sites.&#xD;
&#xD;
               -  Any medical or psychiatric condition which, in the opinion of the investigator or&#xD;
                  the sponsor's medical monitor, would place the patient at risk, interfere with&#xD;
                  participation in the study, or interfere with the interpretation of study results&#xD;
&#xD;
               -  Pregnant or breast-feeding women&#xD;
&#xD;
               -  Known hypersensitivity to ASN002 or its excipients;&#xD;
&#xD;
               -  Prior treatment with SYK or JAK inhibitors for which the subject received no&#xD;
                  clinical benefit, or the subject relapsed whilst on therapy.&#xD;
&#xD;
               -  Has received any marketed or investigational biological agent within 12 weeks or&#xD;
                  5 half-lives (whichever is longer) prior to Day 1.&#xD;
&#xD;
               -  Planned major surgical procedure during the length of the patient's participation&#xD;
                  in this study&#xD;
&#xD;
               -  There will be a waiting period of 4 weeks before receiving the first does for&#xD;
                  anyone who has used oral or intravenous treatments (other than biologics) that&#xD;
                  could affect atopic dermatitis, received a non-biological investigational product&#xD;
                  or device, excessive sun exposure, is planning a trip to a sunny climate, or has&#xD;
                  used tanning booths, or received or plans to receive a live attenuated vaccine&#xD;
                  one four weeks after the last day of taking the drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Zammit, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Asana BioSciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Skin and Dermatology Center, PC.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.A. Universal Research Center, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revival Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leavitt Medical Associates of Florida</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Center of Indiana, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research, Inc.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center for Clinical Research</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologists of Greater Colombus</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermDox Centers for Dermatology</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovate Research, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Skin Advancement Medical, Surgical, Costmetic &amp; Laser Dermatology</name>
      <address>
        <city>Calgary</city>
        <zip>T3A2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc.</name>
      <address>
        <city>Montreal</city>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ontario Inc.</name>
      <address>
        <city>Ottawa</city>
        <zip>K2C3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Regional Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewLab Clinical Research, Inc.</name>
      <address>
        <city>Saint John's</city>
        <zip>A1C2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AvantDerm</name>
      <address>
        <city>Toronto</city>
        <zip>M5A3R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinWISE Dermatology</name>
      <address>
        <city>Winnipeg</city>
        <zip>ABR3M3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim</name>
      <address>
        <city>Bad Bentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn AöR</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MENSINGDERMA research GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 20, 2021</submitted>
    <returned>June 14, 2021</returned>
    <submitted>July 20, 2021</submitted>
    <returned>August 10, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

